Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.48 USD | -1.69% |
|
+4.50% | +109.64% |
May. 30 | Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating | MT |
May. 07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
Chart calendar ADC Therapeutics SA
Upcoming events on ADC Therapeutics SA
Past events on ADC Therapeutics SA
2024-06-06 11:30 am | Jefferies Global Healthcare Conference |
2024-05-20 02:00 pm | H.C. Wainwright BioConnect Investor Conference |
2024-05-14 01:35 pm | RBC Capital Markets Global Healthcare Conference |
2024-05-06 08:30 am | Q1 2024 Earnings Call |
2024-05-06 07:00 am | Q1 2024 Earnings Release |
2024-04-09 06:05 pm | American Association for Cancer Research Meeting - Abstract No: 6573 |
2024-04-09 04:00 pm | Investor Meeting |
2024-04-09 12:00 pm | American Association for Cancer Research Meeting - Abstract No: 5085 |
2024-04-08 04:30 pm | American Association for Cancer Research Meeting - Abstract No: 3122 |
2024-04-08 12:00 pm | American Association for Cancer Research Meeting - Abstract No: CT059 |
2024-04-07 04:30 pm | American Association for Cancer Research Meeting - Abstract No: LB022 |
2024-04-07 04:30 pm | American Association for Cancer Research Meeting - Abstract No: 875 |
2024-03-13 08:30 am | Q4 2023 Earnings Call |
2024-03-13 07:00 am | Q4 2023 Earnings Release |
2024-03-12 09:30 am | Guggenheim Healthy Altitudes Summit |
2024-03-05 09:50 am | TD Cowen Health Care Conference |
2023-12-11 09:00 pm | American Society of Hematology Meeting - Abstract: 4469 |
2023-12-11 08:45 pm | American Society of Hematology Meeting - Abstract: 984 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract: 3133 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract: 3097 |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 2,34 | 0,00 1,03 - | 33,9 33,0 2.77% | 210 204 2.8% | 69,6 68,3 1.9% | 77,8 |
EBITDA Million USD | Released Forecast Spread | 0,00 | -179 -199 9.92% | -199 -245 19.1% | -72,0 -95,0 24.26% | 0,00 0,00 - | 0,00 |
EBIT Million USD | Released Forecast Spread | 0,00 | -219 -197 -11.52% | -262 -258 -1.29% | -124 -130 4.84% | -166 -169 1.93% | -144 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -246 -241 -2.21% | -252 -263 4.36% | -155 -152 -2.02% | -195 -203 3.88% | -171 |
Net income Million USD | Released Forecast Spread | 0,00 | -246 -243 -1.27% | -230 -264 13.01% | -156 -149 -4.68% | -240 -196 -22.23% | -179 |
EPS USD | Released Forecast Spread | -2,36 | -3,77 -3,53 -6.86% | -3,00 -3,36 10.78% | -1,99 -1,90 -4.46% | -2,94 -2,39 -22.81% | -1,89 |
Announcement Date | 24/04/20 | 18/03/21 | 03/03/22 | 28/02/23 | 13/03/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 46,5 37,1 25.28% | 17,3 31,2 -44.62% | 76,3 47,0 62.36% | 69,8 65,5 6.58% | 19,0 20,1 -5.47% | 19,3 20,1 -3.95% | 14,5 15,2 -4.39% | 16,8 15,3 10.02% | 18,1 18,1 -0.27% | 18,9 | 19,8 | 20,3 | 21,3 | 22,3 |
EBIT Million USD | Released Forecast Spread | -40,4 -48,2 16.25% | -69,4 -60,2 -15.25% | -3,11 -43,3 92.81% | -10,7 -19,4 44.69% | -51,6 -59,9 13.94% | -39,8 -40,2 1.11% | -37,4 -45,3 17.36% | -40,0 -40,4 1.14% | -33,6 -39,9 15.86% | -36,5 | -36,9 | -37,5 | -35,7 | -36,1 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -17,8 -52,7 66.16% | -65,3 -72,6 10.09% | -51,3 -52,5 2.31% | -20,2 -23,9 15.36% | -59,7 -47,5 -25.6% | -53,7 -46,2 -16.19% | -47,9 -52,3 8.5% | -39,9 -42,1 5.32% | -45,8 -44,3 -3.38% | -41,7 | -42,0 | -42,5 | -44,3 | -44,8 |
Net income Million USD | Released Forecast Spread | -16,7 -49,0 65.98% | -64,4 -62,3 -3.3% | -50,6 -44,7 -13.24% | -24,2 -17,5 -38% | -59,4 -49,9 -19.07% | -47,1 -46,6 -1.02% | -47,8 -52,0 8.02% | -85,0 -42,1 -101.91% | -46,6 -46,3 -0.75% | -42,0 | -42,3 | -49,6 | -44,3 | -44,8 |
EPS USD | Released Forecast Spread | -0,22 -0,67 67.33% | -0,84 -0,81 -4.22% | -0,65 -0,57 -13.64% | -0,30 -0,21 -43.18% | -0,74 -0,64 -15.64% | -0,58 -0,57 -1.75% | -0,58 -0,63 8.46% | -1,03 -0,50 -105.18% | -0,56 -0,56 -0.76% | -0,44 | -0,43 | -0,48 | -0,43 | -0,44 |
Announcement Date | 09/05/22 | 09/08/22 | 08/11/22 | 28/02/23 | 09/05/23 | 08/08/23 | 07/11/23 | 13/03/24 | 06/05/24 | - | - | - | - | - |
Past sector events for ADC Therapeutics SA
2024-06-05 03:51 am | PHARMAESSENTIA CORPORATION: May 2024 Sales and Revenue Release |
2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
2024-05-15 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ADCT Stock
- Calendar ADC Therapeutics SA